<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605967</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2201</org_study_id>
    <nct_id>NCT02605967</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001
      versus investigator's choice of chemotherapy in patients with advanced NPC.

      By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, PDR001 leads to the
      activation of a T cell mediated antitumor immune response
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2016</start_date>
  <completion_date type="Anticipated">May 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>approximately 20 months after FPFV</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite serum pharmacokinetics (PK) parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameters area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and /or concentration of anti-PDR001 antibodies</measure>
    <time_frame>1 year</time_frame>
    <description>Assess immunogenicity serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune related progression free survival (irPFS) using central assessment</measure>
    <time_frame>2 years</time_frame>
    <description>evaluate the anti-tumor activity of PDR001 versus investigator choice of chemotherapy in NPC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum concentration vs.time profiles</measure>
    <time_frame>1 year</time_frame>
    <description>serum concentration of PDR001 on D1,D8,D15,D29,D36,D43,D57,D58,D64,D71,D85,D140</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential associations between expression of PD-L1, CD8 and other immunological markers with anti-tumor activity</measure>
    <time_frame>2 years</time_frame>
    <description>assess changes in expression of immunological markers such as CD8 and PD-L1 in tumor biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of immune-related genes (RNA/protein in tumor sample</measure>
    <time_frame>2 years</time_frame>
    <description>assess changes in immune-related gene signature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral, soluble ligands and cytokine levels</measure>
    <time_frame>2 years</time_frame>
    <description>assess plasma concentration levels of cytokines interferon-gamma ( IFN-γ) in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite serum pharmacokinetics (PK) parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameters maximum plasma concentration(Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite serum pharmacokinetics (PK) parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameter as the time to reach maximum peak plasma (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite serum pharmacokinetics (PK) parameters</measure>
    <time_frame>1 year</time_frame>
    <description>characterize the pharmacokinetics profiles of PDR001; PK parameters include the elimination half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral, soluble ligands and cytokine levels</measure>
    <time_frame>2 years</time_frame>
    <description>assess plasma concentration levels of cytokines as tumor necrosis factor-alpha (TNF-α) in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral, soluble ligands and cytokine levels</measure>
    <time_frame>2 years</time_frame>
    <description>assess plasma concentration levels of cytokines as Interleukin-6 ( IL-6) in pg/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PDR001 - Investigational drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti-PD1 humanized monoclonal antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>commonly used chemotherapy as per investigator's choice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.</description>
    <arm_group_label>PDR001 - Investigational drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigator choice of chemotherapy</intervention_name>
    <description>commonly used chemotherapy as per investigator's choice</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented non-keratinizing locally advanced recurrent or metastatic
             NPC.

          -  Must be resistant to platinum-based chemotherapy (defined as progression on or after
             platinum-based chemotherapy given in the recurrent/metastatic setting).

          -  May have received at least 1 prior therapy for recurrent or metastatic disease, up to
             2 prior systemic therapies.

          -  An archival tumor specimen or newly obtained tumor sample may be submitted at
             screening/baseline (a fresh tumor sample is preferred), unless agreed differently
             between Novartis and the Investigator.

          -  At least 1 measurable lesion (as per RECIST v1.1) progressing or new since last
             anti-tumor therapy.

          -  Prior treated brain or meningeal metastases must be without MRI evidence of
             progression for at least 8 weeks and off systemic steroids for at least 2 weeks prior
             to screening/baseline.

          -  Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if
             not tested within the past 6 months. If HIV+ positive, patient will be eligible if:
             his/ her CD4+ count ≥ 300/μL; his/her viral load is undetectable; he/she is currently
             receiving highly active antiretroviral therapy (HAART).

        Exclusion Criteria:

          -  History of severe hypersensitivity reactions to other mAbs

          -  Active autoimmune disease or a documented history of autoimmune disease, except
             vitiligo or resolved asthma/atopy that is treated with broncho-dilators.

          -  Active HBV or HCV infections requiring therapy.

          -  Prior PD-1- or PD-L1-directed therapy or any therapeutic cancer vaccine.

          -  Patients receiving systemic treatment with any immunosuppressive medication.

          -  Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within
             4 weeks of initiation of study treatment.

        Other protocol-define inclusion/exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feseha Makonnen</last_name>
      <phone>770-333-2161</phone>
      <email>fmakonnen@gnoc.com</email>
    </contact>
    <investigator>
      <last_name>Steve McCune</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masumeh Alipour</last_name>
      <phone>313-576-8994</phone>
      <email>manicab@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ammar Sukari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Laura and Isaac Perlmutter Cancer Center Laura &amp; Isaac Perlmutter Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zujun Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Cochrane</last_name>
      <phone>703-280-5390</phone>
      <email>monica.cochrane@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 2</city>
        <state>Alpes Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70421</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Kou</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001,</keyword>
  <keyword>nasopharyngeal cancer,</keyword>
  <keyword>moderately differentiated/undifferentiated,</keyword>
  <keyword>locally advanced,</keyword>
  <keyword>recurrent or metastatic NPC,</keyword>
  <keyword>after first- line platinum-based therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

